Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Danish pharma giant Novo Nordisk has been tight-lipped about its next generation fat-melting shot, CagriSema, after disappointing trial results were published last year. The new cocktail drug ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

The market overreacted to CagriSema trial results, causing a 20% stock drop, despite promising 22.7% weight loss results. I believe the market's reaction to CagriSema is disproportionate and doesn ...